Single B Cell Cloning and Production of Rabbit Monoclonal Antibodies

2019 ◽  
pp. 423-441 ◽  
Author(s):  
Juliet Rashidian ◽  
Joshua Lloyd
Keyword(s):  
Monoclonal Antibodies ◽  
B Cell ◽  
Cell Cloning

scholarly journals A method for the isolation and characterization of functional murine monoclonal antibodies by single B cell cloning

2017 ◽  
Vol 448 ◽  
pp. 66-73 ◽  
Author(s):  
Sara Carbonetti ◽  
Brian G. Oliver ◽  
Vladimir Vigdorovich ◽  
Nicholas Dambrauskas ◽  
Brandon Sack ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
B Cell ◽  
Cell Cloning ◽  
Isolation And Characterization ◽  
Murine Monoclonal Antibodies

scholarly journals The fate of fetal and adult B-cell progenitors grafted into immunodeficient CBA/N mice.

1979 ◽  
Vol 150 (3) ◽  
pp. 548-563 ◽  
Author(s):  
C J Paige ◽  
P W Kincade ◽  
M A Moore ◽  
G Lee
Keyword(s):  
B Cells ◽  
B Cell ◽  
Fetal Liver ◽  
Cell Cloning ◽  
Generate Functional ◽  
Self Renewal ◽  
Relative Ability ◽  
Cloning Assay ◽  
Regenerative Ability

The relative ability of various precursors to generate functional B cells in vivo was assessed by transferring normal, chromosomally-marked CBA/H-T6T6 cells to irradiated or unirradiated immunodeficient CBA/N mice. Emergence of donor-derived B cells was monitored by means of a B-cell cloning assay (in which CBA/N cells are inactive), and by karyotpic analysis of lymphoid, myeloid, and stem cell metaphases. Grafts of lymph node, spleen, anti-mu surface immunoglobin suppressed bone marrow, sIg+ cell-depleted marrow, normal marrow, fetal liver, and yolk sac suggest: (a) there is little self-renewal of sIg+ B cells in these models; (b) pre-committed cells have extensive proliferative/differentiative potential and at least initially contribute most of the newly-formed B cells; (c) populations or pre-B cells obtained from various sources differ in their regenerative ability; (d) CBA/N mice are deficient in a category of pre-B cells which are found in fetal liver; and (e) selective B-cell chimerism results from grafting of unirradiated CBA/N mice.

scholarly journals Antibody-based therapy of leukaemia

2009 ◽  
Vol 11 ◽  
Author(s):  
John C. Morris ◽  
Thomas A. Waldmann
Keyword(s):  
Monoclonal Antibodies ◽  
T Cell ◽  
B Cell ◽  
Gemtuzumab Ozogamicin ◽  
Cell Leukaemia ◽  
Target Cells ◽  
Immune Effector ◽  
Effector Cells ◽  
Prolymphocytic Leukaemia ◽  
Immune Effector Cells

Over the past decade, monoclonal antibodies have dramatically impacted the treatment of haematological malignancies, as evidenced by the effect of rituximab on the response rate and survival of patients with follicular and diffuse large B cell non-Hodgkin's lymphoma. Currently, only two monoclonal antibodies – the anti-CD33 immunotoxin gemtuzumab ozogamicin and the CD52-directed antibody alemtuzumab – are approved for treatment of relapsed acute myeloid leukaemia in older patients and B cell chronic lymphocytic leukaemia, respectively. Although not approved for such treatment, alemtuzumab is also active against T cell prolymphocytic leukaemia, cutaneous T cell lymphoma and Sézary syndrome, and adult T cell leukaemia and lymphoma. In addition, rituximab has demonstrated activity against B cell chronic lymphocytic and hairy cell leukaemia. Monoclonal antibodies targeting CD4, CD19, CD20, CD22, CD23, CD25, CD45, CD66 and CD122 are now being studied in the clinic for the treatment of leukaemia. Here, we discuss how these new antibodies have been engineered to reduce immunogenicity and improve antibody targeting and binding. Improved interactions with Fc receptors on immune effector cells can enhance destruction of target cells through antibody-dependent cellular cytotoxicity and complement-mediated cell lysis. The antibodies can also be armed with cellular toxins or radionuclides to enhance the destruction of leukaemia cells.

Monoclonal antibodies that block adhesion of B cell progenitors to bone marrow stromain vitro prevent B cell differentiationin vivo

1991 ◽  
Vol 21 (9) ◽  
pp. 2043-2049 ◽  
Author(s):  
Beat A. Imhof ◽  
Claude Schlienger ◽  
Klaus Handloser ◽  
Barbara Hesse ◽  
Michaela Slanicka ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Monoclonal Antibodies ◽  
B Cell

Cells Reactive with Anti-T-Cell Monoclonal Antibodies in Malignant Cutaneous B-Cell Lymphomas and Pseudolymphomas

1984 ◽  
Vol 10 (4) ◽  
pp. 313-314 ◽  
Author(s):  
PETER KAUDEWITZ ◽  
GÜNTER BURG ◽  
K. KLEPZIG ◽  
R. MUNKER ◽  
P. RIEBER ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
T Cell ◽  
B Cell ◽  
B Cell Lymphomas

scholarly journals Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs

2015 ◽  
Vol 75 (10) ◽  
pp. 1866-1875 ◽  
Author(s):  
Elisa Corsiero ◽  
Michele Bombardieri ◽  
Emanuela Carlotti ◽  
Federico Pratesi ◽  
William Robinson ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
B Cells ◽  
Single Cell ◽  
Cell Cloning ◽  
Single Cell Cloning

scholarly journals Investigational Immunotherapeutics for B-Cell Malignancies

2010 ◽  
Vol 28 (5) ◽  
pp. 884-892 ◽  
Author(s):  
Alfonso Quintás-Cardama ◽  
William Wierda ◽  
Susan O'Brien
Keyword(s):  
Monoclonal Antibodies ◽  
B Cell ◽  
Acquired Resistance ◽  
Long Term Outcomes ◽  
Clinical Value ◽  
B Cell Malignancies ◽  
Therapeutic Algorithms ◽  
Number Of Patients

The use of rituximab-based chemoimmunotherapy regimens has remarkably improved the response rates, long-term outcomes, and quality of life of patients with B-cell malignancies. However, a substantial number of patients exhibit either primary or acquired resistance to rituximab, which suggests that novel immunotherapeutics with distinct mechanisms of action are necessary. A series of monoclonal antibodies with specificity against different surface antigens expressed on malignant B cells (eg, CD22, CD23, CD40, CD70) and novel immunotherapeutics (eg, bispecific monoclonal antibodies, small-modular immunopharmaceuticals, T-cell engagers) are currently in clinical or final preclinical stages of development. Although these agents offer reason for optimism, considerable challenges lie ahead in establishing their real clinical value, as well as in integrating them into current therapeutic algorithms for patients with B-cell malignancies. This review describes some of the most promising investigational immunotherapeutics for the treatment of B-cell malignancies.

Immunohistological Diagnosis of Primary Brain Lymphoma Using Monoclonal Antibodies: Confirmation of B—Cell Origin

1988 ◽  
Vol 14 (1) ◽  
pp. 19-37 ◽  
Author(s):  
J. A. GARSON ◽  
S. P. BOURNE ◽  
P. M. ALLAN ◽  
C. LEATHER ◽  
D. B. BROWNELL ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
B Cell ◽  
Brain Lymphoma ◽  
Primary Brain Lymphoma
Sign in / Sign up

Export Citation Format

Share Document